Phase 3 NCT07552389 Trial: HL1113R1/R2 vs HL1113 in Hypertension and Diabetes
Summary
Phase 3 clinical trial NCT07552389 registered April 27, 2026, evaluating HL1113R1/R2 monotherapy versus HL1113 fixed-dose combination in patients with essential hypertension and type II diabetes mellitus. The multi-center, randomized, double-blind study will assess efficacy and safety across four intervention groups (test, exploratory test, and two control groups). Pharmaceutical manufacturers, clinical research organizations, and healthcare institutions involved in diabetes and cardiovascular research should monitor this trial for competitive intelligence and patient recruitment updates.
“This clinical trial is a randomized, active controlled, double blind, parallel, multi center, phase 3 study to evaluate the efficacy and safety of monotherapy group of HL1113R1 or HL1113R2 versus HL1113 (Fixed dose combination) in patients with essential hypertension and type II diabetes mellitus”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
Phase 3 clinical trial NCT07552389 registered on April 27, 2026, evaluating HL1113R1/R2 monotherapy versus HL1113 fixed-dose combination in patients with essential hypertension and type II diabetes mellitus. The multi-center, randomized, double-blind study will assess efficacy and safety across four intervention groups.
Pharmaceutical manufacturers, clinical research organizations, and healthcare institutions involved in diabetes and cardiovascular research should monitor this trial for competitive intelligence and patient recruitment updates.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Clinical Trial to Evaluate the Efficacy and Safety of Monotherapy Group of HL1113R1 or HL1113R2 Versus HL1113 (Fixed Dose Combination) in Patients With Essential Hypertension and Type II Diabetes Mellitus
Phase 3 NCT07552389 Kind: PHASE3 Apr 27, 2026
Abstract
This clinical trial is a randomized, active controlled, double blind, parallel, multi center, phase 3 study to evaluate the efficacy and safety of monotherapy group of HL1113R1 or HL1113R2 versus HL1113 (Fixed dose combination) in patients with essential hypertension and type II diabetes mellitus
Conditions: Hypertension, Diabete Type 2
Interventions: Test group, Exploratory test group, Control group 1, Control group 2
Mentioned entities
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.